Olaparib

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.

The FDA approved olaparib in combination with abiraterone acetate and prednisone or prednisolone for men with suspected deleterious or deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.

An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.

The combination of olaparib and the investigational ATR inhibitor ceralasertib induced antitumor responses in children and adolescents with DNA repair-deficient tumors, according to phase 1 results of the AcSé-ESMART trial.

Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Talazoparib appeared effective among certain patients with advanced, PALB2-mutated breast cancer, according to study results published in Nature Cancer.

Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.

The FDA granted priority review to olaparib as part of combination therapy treatment of metastatic castration-resistant prostate cancer.

Adjuvant olaparib significantly extended OS among patients with HER2-negative high-risk early-stage breast cancer and germline BRCA1/BRCA2 mutations, according to results of the randomized phase 3 OlympiA study.